Company profile
MESOBLAST LTD
NASDAQ:MESOBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| REMESTEMCEL-L | phase3 | — | 9 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (34)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01851070 | phase2 | completed | 2013-07-01 | 2016-05-01 | Mesoblast, Ltd. | A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor |
| NCT00225095 | phase1_2 | completed | 2005-09-01 | 2008-04-01 | Mesoblast International Sàrl | A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy |
| NCT00721045 | phase2 | completed | 2008-08-01 | 2011-06-01 | Mesoblast, Ltd. | A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure |
| NCT02336230 | phase3 | completed | 2015-06-04 | 2018-04-09 | Mesoblast, Inc. | A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) |
| NCT07568535 | phase3 | not_yet_recruiting | 2026-08-31 | 2028-02-28 | Mesoblast, Ltd. | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125706 | BLA | Mesoblast, Inc. | ||||
Loading… | ||||||